Study sharpens cefquinome dosing picture in lactating sheep and goats

A new Veterinary Sciences paper takes a closer look at how cefquinome behaves in lactating sheep and goats after intravenous, subcutaneous, and long-acting subcutaneous administration, using nonlinear mixed-effects modeling and Monte Carlo simulations to estimate PK/PD target attainment. The study stands out because it focuses on lactating small ruminants and includes a long-acting formulation, an area where published cefquinome data have been relatively sparse. (papers.ssrn.com)

That matters because cefquinome has long been used in food-animal medicine outside the U.S., but small-ruminant evidence has lagged behind cattle and swine. Earlier published work examined cefquinome in goats across physiologic states, showing lactation can alter drug disposition and that recommended regimens may need to be adjusted to reach PK/PD targets. Older sheep-and-goat work also suggested similar intramuscular pharmacokinetics between the two species, but those studies did not answer the newer question of how long-acting administration performs in lactating animals. (pubmed.ncbi.nlm.nih.gov)

According to the study summary, cefquinome showed low volumes of distribution, roughly 0.21 to 0.31 L/kg, in lactating sheep and goats, consistent with a drug that remains largely in extracellular fluid. The authors used population modeling and Monte Carlo simulation to compare routes and estimate whether exposures would likely meet pharmacodynamic targets against relevant pathogens. The key practical finding is that route matters: long-acting subcutaneous dosing can extend exposure, but that doesn’t automatically translate into optimal target attainment if peak concentrations are too low or if pathogen MICs are less favorable. (papers.ssrn.com)

The paper also fits into a broader line of work from related research groups studying cephalosporin PK/PD in goats. A 2021 goat study published in Journal of Veterinary Pharmacology and Therapeutics found lactation increased central volume and altered absorption-related parameters, while milk penetration was minimal. That study concluded goats may require higher dose intensity than cattle or pigs to achieve PK/PD targets for some respiratory pathogens, reinforcing the idea that extrapolating from other species can be misleading. (pubmed.ncbi.nlm.nih.gov)

Industry or outside expert reaction to this specific paper wasn’t readily visible in press coverage, but the stewardship context is clear. WHO classifies third- and fourth-generation cephalosporins among the critically important antimicrobials for human medicine, and EMA’s prior cephalosporin referral concluded that systemically administered third- and fourth-generation cephalosporins in food-producing species should carry tighter product-information restrictions. In practice, that means any new dosing paper on cefquinome is likely to be read through two lenses at once: efficacy optimization and antimicrobial stewardship. (who.int)

Why it matters: For veterinarians working with dairy sheep and goats, this kind of modeling study can support more rational treatment planning, especially when long-acting formulations are being considered for labor, compliance, or handling reasons. But it also underscores a familiar tension: convenience can’t substitute for PK/PD target attainment, and target attainment can’t substitute for residue compliance. Earlier work with related cephalosporins in lactating goats has shown why milk disposition and withdrawal considerations remain central in this population. (bmcvetres.biomedcentral.com)

There’s also a regulatory nuance for U.S. readers. FDA’s Green Book and Animal Drugs @ FDA database are the authoritative sources for approved animal drugs in the United States, and they’re the right place to verify whether a product is approved and labeled for a given species and indication. So even though cefquinome has an established place in some international markets, this paper is probably most useful to U.S. veterinarians as scientific background on cephalosporin PK/PD in small ruminants, not as a signal of an immediate domestic practice change. (fda.gov)

What to watch: The next meaningful step would be studies that connect these modeled exposures to real-world outcomes, including clinical cure, bacteriologic response, milk residues, and defensible withdrawal intervals in lactating flocks and herds. If those data emerge, they’ll do more than refine dose theory, they’ll determine whether long-acting cefquinome can be used in a way that is both effective and stewardship-aligned. (bmcvetres.biomedcentral.com)